Bisphosphonate-related atypical femoral fracture: Managing a rare but serious complication

Stuart Silverman; Eli Kupperman; Susan Bukata

doi:10.3949/ccjm.85a.17119

Bisphosphonate-related atypical femoral fracture: Managing a rare but serious complication

Cleve Clin J Med. 2018 Nov;85(11):885-893. doi: 10.3949/ccjm.85a.17119.

Authors

Stuart Silverman^{1

2

3}, Eli Kupperman⁴, Susan Bukata³

Affiliations

¹ Cedars-Sinai Medical Center, Los Angeles, CA, USA.
² Medical Director, OMC Clinical Research Center, Beverly Hills, CA, USA. [email protected].
³ David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
⁴ Department of Orthopaedic Surgery, University of California, Los Angeles, CA, USA.

PMID: 30395525
DOI: 10.3949/ccjm.85a.17119

Abstract

Atypical femoral fracture is a rare but serious complication of long-term bisphosphonate therapy. Although the benefit of preventing osteoporotic fractures greatly outweighs the risk of atypical fracture in bisphosphonate users, concern about atypical fracture risk has led to a decrease in bisphosphonate use. What are the risks, and how do we treat atypical femoral fracture?

Publication types

Review

MeSH terms

Aged
Bone Density Conservation Agents / adverse effects*
Diphosphonates / adverse effects*
Female
Femoral Fractures / chemically induced*
Humans
Male
Osteoporosis / complications
Osteoporosis / drug therapy*
Osteoporotic Fractures / prevention & control*
Time Factors

Substances

Bone Density Conservation Agents
Diphosphonates